Arcellx Acquired by Gilead Sciences | Healthcare M&A Deal

Gilead Sciences has acquired Arcellx, a healthcare services other business in California, for $115. Arcellx acquisition targets a healthcare services other platform focused on developing and commercializing oncology and immunology therapies, supporting Gilead Sciences acquisitions in the U.S. market. Gilead Sciences acquisitions in healthcare M&A aim to expand clinical pipeline depth and strengthen therapeutic capabilities through merger acquisition of Arcellx. The strategic acquisition is structured as a merger acquisition, with Gilead Sciences as a strategic buyer and Arcellx as the target, and the deal is announced with an undisclosed size.